Alembic Pharmaceuticals Limited (APLLTD) Price & Analysis

Compare

2 Followers

APLLTD Stock Chart & Stats

₹930.30

-₹4.90(-0.46%)

At close: Jan 09 4:00 PM EST

₹930.30

-₹4.90(-0.46%)

Day’s Range― - ―

52-Week Range₹725.60 - ₹1,107.80

Previous CloseN/A

Volume60.71K

Average Volume (3M)9.71K

Market Cap

₹152.58B

Enterprise Value₹163.44B

Total Cash (Recent Filing)₹834.80M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)24.3

Beta0.99

Next Earnings

May 06, 2026

EPS Estimate

8.27

Next Dividend Ex-DateN/A

Dividend Yield1.28%

Share Statistics

EPS (TTM)8.90

Shares Outstanding196,563,130

10 Day Avg. Volume3,953

30 Day Avg. Volume9,706

Financial Highlights & Ratios

PEG Ratio-5.74

Price to Book (P/B)3.40

Price to Sales (P/S)2.64

P/FCF Ratio-37.06

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diversified Revenue StreamsAlembic's multi-pronged model — domestic branded formulations, regulated-market generics, an API manufacturing arm and contract manufacturing potential — provides durable revenue diversification. This reduces single-market exposure and supports steadier cash flows and resilience versus peers over months.

Revenue Growth And Margin ImprovementConsistent revenue growth with improving gross and EBIT margins signals structural operating leverage and pricing/volume strength. Sustained margin expansion supports internal reinvestment and competitive positioning, improving free cash generation potential over a 2–6 month horizon if trends continue.

Healthy Equity Base And ROEA strong equity base and robust ROE indicate efficient use of shareholder capital and provide a buffer against shocks. This financial foundation supports ongoing R&D, market expansion and creditor confidence, helping maintain strategic options and investment capacity over the medium term.

Bears Say

Weak Cash Conversion / Negative FCFReduced free cash flow and a weaker operating-cash-to-net-income ratio signal difficulty converting profits into spendable cash. Persisting negative FCF constrains dividends, debt reduction and growth investments, increasing reliance on external financing and raising execution risk over coming months.

Rising LeverageAn uptick in debt-to-equity raises interest and refinancing exposure and narrows financial flexibility. If leverage continues to rise while cash conversion lags, funding costs and covenant risks could intensify, limiting strategic initiatives and heightening vulnerability to macro tightening over 2–6 months.

Net Margin Volatility / Cost Control IssuesFluctuating net margins point to inconsistent cost control or pricing pressures. Margin volatility undermines predictable free cash generation and capital allocation, complicating long-term planning and potentially reducing returns on new product launches or market expansion if not stabilized.

Alembic Pharmaceuticals Limited News

Alembic Pharmaceuticals Board Clears Q3 FY26 Unaudited Results, Appoints New Non-Executive Director

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has provided an update. Alembic Pharmaceuticals Limited’s Board of Directors has approved...

17d ago

Alembic Pharmaceuticals Sets Q3 FY26 Post-Results Call for Investors

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has scheduled a post-results...

1M ago

Alembic Pharmaceuticals Schedules Investor Meeting with ICICI Prudential

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals Limited has announced a...

3M ago

Alembic Pharmaceuticals Gains USFDA Approval for Diltiazem Tablets

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an update. Alembic Pharmaceuticals Limited has received final approval from...

3M ago

Alembic Pharmaceuticals Initiates Transfer of Unclaimed Shares

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals Limited has announced a...

3M ago

Alembic Pharmaceuticals Schedules Post-Results Conference Call

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals Limited has announced a...

4M ago

Alembic Pharmaceuticals Updates Registrar’s Email for Improved Communication

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has shared an update. Alembic Pharmaceuticals Limited has announced a change in...

5M ago

Alembic Pharmaceuticals Gains USFDA Approval for Tretinoin Cream

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals Limited has announced that it received...

6M ago

Alembic Pharmaceuticals Hosts 15th AGM Virtually, Engages Stakeholders

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals Limited held its 15th...

7M ago

Alembic Pharmaceuticals Announces New Auditor Appointments

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals Limited announced a change...

7M ago

APLLTD FAQ

What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?

Alembic Pharmaceuticals Limited lowest stock price was ₹725.60 and its highest was ₹1107.80 in the past 12 months.

What is Alembic Pharmaceuticals Limited’s market cap?

Alembic Pharmaceuticals Limited’s market cap is ₹152.58B.

When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?

Alembic Pharmaceuticals Limited’s upcoming earnings report date is May 06, 2026 which is in 73 days.

How were Alembic Pharmaceuticals Limited’s earnings last quarter?

Alembic Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹8.9 earnings per share for the quarter, beating the consensus estimate of ₹8.372 by ₹0.528.

Is Alembic Pharmaceuticals Limited overvalued?

According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Pharmaceuticals Limited pay dividends?

Alembic Pharmaceuticals Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.28%. See more information on Alembic Pharmaceuticals Limited dividends here

What is Alembic Pharmaceuticals Limited’s EPS estimate?

Alembic Pharmaceuticals Limited’s EPS estimate is 8.27.

How many shares outstanding does Alembic Pharmaceuticals Limited have?

Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.

What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?

Alembic Pharmaceuticals Limited reported an EPS of ₹8.9 in its last earnings report, beating expectations of ₹8.372. Following the earnings report the stock price went up 1.409%.

Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:APLLTD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.